[1] Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and child-pugh A versus B cirrhosis . Gastrointest Cancer Res, 2011, 4: 40-44.
[2] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359:378-390.
[3] Bozova S, Elpek GO. Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS, 2007,115:795-801.
[4] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009,10:25-34.
[5] Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol, 2000, 35:71-103.
[6] Faloppi L, Scartozzi M, Bianconi M, et al. The role of LDH serum levels in predicting global outcome in HCC
patients treated with sorafenib: implications for clinical management. BMC Cancer, 2014,14:110.
[7] Faloppi L, Bianconi M, Giampieri R, et al. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015,6:35087-35094.
[8] Kubackova K, Bortlicek Z, Pavlik T, et al. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Target Oncol, 2015;10:385-392.
[9] Sacco R, Mismas V, Granito A, et al. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. Int J Biol Markers, 2015,30:e65-72. |
